ACRS vs PTGX vs IMVT vs ARDX vs ABBV

For growth investors, Ardelyx, Inc.

(ARDX) is the stronger pick with 22. 1% revenue growth year-over-year, versus -89. 4% for Protagonist Therapeutics, Inc. (PTGX). AbbVie Inc. (ABBV) offers the better valuation at 85. 5x trailing P/E (14. 3x forward), making it the more compelling value choice. Analysts rate Aclaris Therapeutics, Inc. (ACRS) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, AbbVie Inc.

is actually cheaper at 14. 3x.

Over the past 5 years, Ardelyx, Inc.

(ARDX) delivered a total return of +313. 0%, compared to -78. 8% for Aclaris Therapeutics, Inc. (ACRS). Over 10 years, the gap is even starker: PTGX returned +744. 9% versus ACRS's -76. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Protagonist Therapeutics, Inc.

(PTGX) is the lower-risk stock at 0. 25β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 448% more volatile than PTGX relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 127% for Ardelyx, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ardelyx, Inc.

(ARDX) is pulling ahead at 22. 1% versus -89. 4% for Protagonist Therapeutics, Inc. (PTGX). On earnings-per-share growth, the picture is similar: Aclaris Therapeutics, Inc. grew EPS 69. 0% year-over-year, compared to -148. 5% for Protagonist Therapeutics, Inc.. Over a 3-year CAGR, ARDX leads at 98. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AbbVie Inc.

(ABBV) is the more profitable company, earning 6. 9% net margin versus -829. 6% for Aclaris Therapeutics, Inc. — meaning it keeps 6. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus -975. 9% for ACRS. At the gross margin level — before operating expenses — PTGX leads at 97. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, AbbVie Inc.

(ABBV) trades at 14. 3x forward P/E versus 30. 6x for Protagonist Therapeutics, Inc. — 16. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ARDX: 143. 6% to $17. 00.

In this comparison, ABBV (3.

2% yield) pays a dividend. ACRS, PTGX, IMVT, ARDX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34), 3. 2% yield, +295. 5% 10Y return). Both have compounded well over 10 years (ABBV: +295. 5%, IMVT: +173. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ACRS is a small-cap quality compounder stock; PTGX is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock; ARDX is a small-cap high-growth stock; ABBV is a large-cap income-oriented stock. ABBV pays a dividend while ACRS, PTGX, IMVT, ARDX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.